Detalles de la búsqueda
1.
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial.
Lancet Haematol
; 10(3): e191-e202, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36764323
2.
Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy.
J Immunother
; 45(3): 150-161, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35191428
3.
Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.
Leuk Lymphoma
; 60(4): 1043-1052, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30277098
4.
Highly Aggressive Metastatic Melanoma Cells Unable to Maintain Telomere Length.
Cell Rep
; 19(12): 2529-2543, 2017 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-28636941
Resultados
1 -
4
de 4
1
Próxima >
>>